An observational study in Retinal Light Damage, Photic Retinopathy and Photic Maculopathy, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Recruiting at 1 site in China. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this retrospective observational study is to evaluate the effectiveness of retrobulbar glucocorticoid injection in patients with retinal photo-injury. The main questions it aims to answer are:
Does retrobulbar glucocorticoid injection improve visual outcomes in patients with retinal photo-injury? Does retrobulbar glucocorticoid injection promote recovery of retinal structural and microvascular changes assessed by optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA)? Patients with retinal photo-injury will be retrospectively identified and grouped according to the treatment they received. Clinical and ophthalmic data collected before treatment and during follow-up for up to 6 months will be reviewed, including best-corrected visual acuity (BCVA), fundus photography, spectral-domain OCT (SD-OCT), and OCTA. Visual and retinal imaging outcomes will be compared between the two groups to evaluate the potential effectiveness of retrobulbar glucocorticoid treatment.
Second Affiliated Hospital, Zhejiang University, School of Medicine is the lead sponsor of 100 studies on the registry; 68 are open to participants now.
Counted across the registry records on this site, refreshed daily.
patients diagnosed with retinal photic injury
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The included patient should meet the aforementioned diagnostic criteria, and was diagnosed with retinal photic injury.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with retinal photic injury who only received intravitreal corticosteroid injections during their initial visit and follow-ups were placed in the local hormone treatment group.
Drug: retrobulbar injection of glucocorticoid
Patients with retinal light damage who didn't use any systemic or local corticosteroid treatment at their first visit or during follow-ups were placed in the non-hormone treatment group.
Retrobulbar injection of Methylprednisolone (40mg/ml) once a week, or triamcinolone (40mg/ml) every 2-3 weeks, no more than 3 times in a row. For children, the dose should be halved or the interval extended, and closely watch for any side effects after injection.
Changes in Best-Corrected Visual Acuity (BCVA), measured in logMAR
Best-corrected visual acuity (BCVA) will be assessed using a standardized visual acuity chart after appropriate refractive correction and recorded as a decimal visual acuity value, which will be converted to the logarithm of the minimum angle of resolution (logMAR) for statistical analysis. BCVA will be assessed at baseline (before treatment) and at 1 week, 2 weeks, 1 month, 3 months, and 6 months after treatment. The BCVA value and the change from baseline at each follow-up time point will be summarized and compared. Lower logMAR values indicate better visual acuity.
Time frame: Before treatment and at 1 week, 2 weeks, 1 month, 3 months, and 6 months after treatment
Changes in Central Subfield Thickness, Ellipsoid Zone Defect Length, and Outer Nuclear Layer Thickness Measured by Optical Coherence Tomography
Retinal structural changes will be assessed using optical coherence tomography (OCT). The following quantitative parameters will be measured: central subfield thickness (CST, μm), maximum horizontal length of the ellipsoid zone (EZ) defect (μm), and foveal outer nuclear layer (ONL) thickness (μm). Measurements will be obtained at baseline (before treatment) and at 1 week, 2 weeks, 1 month, 3 months, and 6 months after treatment. Each parameter and its change from baseline at each follow-up time point will be summarized and compared to evaluate retinal structural recovery following treatment.
Time frame: Before treatment and at 1 week, 2 weeks, 1 month, 3 months, and 6 months after treatment
Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Second Affiliated Hospital, Zhejiang University, School of Medicine →